Loading clinical trials...
Loading clinical trials...
Phase I/Ib First-in-Human Study of EOS100850 (Inupadenant) As a Single Agent and in Combination with Pembrolizumab And/or Chemotherapy in Participants with Advanced Cancers
Conditions
Interventions
EOS100850
Pembrolizumab
+1 more
Locations
19
United States
Karmanos Cancer Institute
Michigan Center, Michigan, United States
John Theurer Cancer Center, Hackensack University Medical Center
Hackensack, New Jersey, United States
University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States
Hospital GZA Sint-Augustinus
Wilrijk, Antwerpen, Belgium
Institut Jules Bordet
Anderlecht, Brussels Capital, Belgium
UCL Saint-Luc
Brussels, Brussels Capital, Belgium
Start Date
February 5, 2019
Primary Completion Date
May 28, 2024
Completion Date
May 28, 2024
Last Updated
September 19, 2024
NCT05223608
NCT06625775
NCT06051695
NCT06265727
NCT04665206
NCT05036226
Lead Sponsor
iTeos Therapeutics
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions